Anti-IL18 drugs are under investigation in AID especially those associated with MAS or neurological/psychiatric manifestations with favorable safety profile and efficacy (Baggio et al., 2023)Koné-Paut and Piram, 2012, Ihim et al., 2022. Here, IL18 is linked to macrophage activation syndrome.